Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

817 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The time-sequential changes of risk factors for adult T-cell leukemia development in human T-cell leukemia virus-positive patients with rheumatoid arthritis: a retrospective cohort study.
Umekita K, Hashiba Y, Kariya Y, Kubo K, Miyauchi S, Aizawa A, Umeki K, Nomura H, Kawaguchi T, Matsuda M, Takajo I, Hidaka T, Okayama A. Umekita K, et al. Among authors: okayama a. Mod Rheumatol. 2019 Sep;29(5):795-801. doi: 10.1080/14397595.2018.1519890. Epub 2018 Oct 25. Mod Rheumatol. 2019. PMID: 30246572
Leukocytapheresis (LCAP) decreases the level of platelet-derived microparticles (MPs) and increases the level of granulocytes-derived MPs: a possible connection with the effect of LCAP on rheumatoid arthritis.
Umekita K, Hidaka T, Ueno S, Takajo I, Kai Y, Nagatomo Y, Sawaguchi A, Suganuma T, Okayama A. Umekita K, et al. Among authors: okayama a. Mod Rheumatol. 2009;19(3):265-72. doi: 10.1007/s10165-009-0164-2. Epub 2009 Apr 1. Mod Rheumatol. 2009. PMID: 19337689
Brief Report: Attenuated Effectiveness of Tumor Necrosis Factor Inhibitors for Anti-Human T Lymphotropic Virus Type I Antibody-Positive Rheumatoid Arthritis.
Suzuki T, Fukui S, Umekita K, Miyamoto J, Umeda M, Nishino A, Okada A, Koga T, Kawashiri SY, Iwamoto N, Ichinose K, Tamai M, Fujikawa K, Aramaki T, Mizokami A, Matsuoka N, Ueki Y, Eguchi K, Sato S, Hidaka T, Origuchi T, Okayama A, Kawakami A, Nakamura H. Suzuki T, et al. Among authors: okayama a. Arthritis Rheumatol. 2018 Jul;70(7):1014-1021. doi: 10.1002/art.40461. Epub 2018 May 25. Arthritis Rheumatol. 2018. PMID: 29471588
Effective Treatment with Tocilizumab in a Rheumatoid Arthritis Patient Complicated with Human T-cell Leukemia Virus Type 1-associated Myelopathy.
Iwao C, Umekita K, Miyauchi S, Kimura M, Rikitake Y, Iwao K, Rikitake M, Aizawa A, Kawaguchi T, Kariya Y, Matsuda M, Takajo I, Shiomi K, Okayama A. Iwao C, et al. Among authors: okayama a. Intern Med. 2020 Aug 1;59(15):1891-1897. doi: 10.2169/internalmedicine.4455-20. Epub 2020 Apr 23. Intern Med. 2020. PMID: 32321893 Free PMC article.
Human T-cell leukemia virus type 1 may invalidate T-SPOT.TB assay results in rheumatoid arthritis patients: A retrospective case-control observational study.
Umekita K, Hashiba Y, Iwao K, Iwao C, Kimura M, Kariya Y, Kubo K, Miyauchi S, Kudou R, Rikitake Y, Takajo K, Kawaguchi T, Matsuda M, Takajo I, Inoue E, Hidaka T, Okayama A. Umekita K, et al. Among authors: okayama a. PLoS One. 2020 May 27;15(5):e0233159. doi: 10.1371/journal.pone.0233159. eCollection 2020. PLoS One. 2020. PMID: 32459801 Free PMC article. Clinical Trial.
Effectiveness and safety of non-tumor necrosis factor inhibitor therapy for anti-human T-cell leukemia virus type 1 antibody-positive rheumatoid arthritis.
Endo Y, Fukui S, Umekita K, Suzuki T, Miyamoto J, Morimoto S, Shimizu T, Koga T, Kawashiri SY, Iwamoto N, Ichinose K, Tamai M, Origuchi T, Okada A, Fujikawa K, Mizokami A, Matsuoka N, Aramaki T, Ueki Y, Eguchi K, Kariya Y, Hashiba Y, Hidaka T, Okayama A, Kawakami A, Nakamura H. Endo Y, et al. Among authors: okayama a. Mod Rheumatol. 2021 Sep;31(5):972-978. doi: 10.1080/14397595.2020.1847802. Epub 2020 Nov 27. Mod Rheumatol. 2021. PMID: 33161771
817 results